Finerenone (Kerendia)

A prescription pill that contains finerenone, a non-steroidal medicine that blocks the mineralocorticoid receptor. In the FIDELIO-DKD trial finerenone lowered the risk of kidney disease getting worse in people with chronic kidney disease and type 2 diabetes. This record does not list approved uses because no Kerendia label record was found.

Also called Kerendia

  • Product
  • In this atlas

Overview

Technical summary

FDA application NDA215341, applicant listed as BAYER HLTHCARE. Original approval on 2021-07-09 (ORIG-1, Type 1 - New Molecular Entity). Dosage form TABLET. openFDA returned no label record for the brand, so no indication text was read.

Product details

Type
Medicine
Model or formulation
Tablet (dosage form TABLET on the openFDA record); several strengths.
Version
Not stated in the sources read. The application covers several strengths and presentations.

Intended-use sources

No intended-use source is recorded.

Claims and evidence

Context United States FDA original approval of a new drug application (NDA)

Recipient
Recipient not specified
Population
Not stated in the FDA application records read. The records give the applicant, the products and the submission history; the label record gives age limits for each indication.
Care setting
Not stated in the FDA records
Geography
United States (decision by the US Food and Drug Administration)
Life stage
Not stated in the FDA records
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    The US Food and Drug Administration approved Kerendia (finerenone tablets) on 9 July 2021 under new drug application NDA215341. The Drugs@FDA page lists the original submission as ORIG-1, an approval, classified Type 1 - New Molecular Entity. The openFDA record lists the applicant as BAYER HLTHCARE.

    Applies to Recipient not specified
    • Not stated in the FDA application records read. The records give the applicant, the products and the submission history; the label record gives age limits for each indication.
    • Not stated in the FDA records
    • United States (decision by the US Food and Drug Administration)
    • Not stated in the FDA records
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (regulatory decision)
    Certainty method
    Not assessed
    Limitations
    An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The date comes from the Drugs@FDA page, which writes it as a month-first slash date. The openFDA record gives the date only as a compact number, so the page is quoted. No label record for Kerendia was returned by openFDA, so this atlas states no indication. openFDA says not to rely on it for decisions about medical care.
    Last checked
    2026-10-14
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record for application NDA215341 returned on 2026-10-14, from a dataset last updated 2026-10-13. It lists the applicant, products and submissions but gives the original approval date only as a compact number (YYYYMMDD), so the Drugs@FDA page is also kept as a snapshot. · NDA: NDA215341

      Locator
      results[0].application_number; results[0].sponsor_name
      How it applies
      Application number and applicant.
      Retrieved
      Source effective date
      2026-10-13
      Source state
      Current
      Snapshot hash
      3ad75e163b866653015aee0b31d67725c3aaf788abe55d149f53d65ab1f3385e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-14 as ch-openfda-terms.html, sha256 b11f712bfb11, hash only). The raw record is committed at research/snapshots/ch-openfda-nda215341.json.
    2. Supports Drugs@FDA: approval date(s) and history for NDA 215341 (Kerendia)

      Regulator · U.S. Food and Drug Administration (Drugs@FDA) · Edition Drugs@FDA application overview page fetched 2026-10-14.

      Locator
      Original Approvals or Tentative Approvals, Action Date (MM/DD/YYYY)
      How it applies
      Original approval date.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Snapshot hash
      1dbf2f78139897b5d65087d562dd452e07f39893a5c534b4c76ec8b0b669d490
      Reuse basis
      The FDA website policies page (fetched 2026-10-14 as ch-fda-website-policies.html, sha256 59b7c8541753, hash only) says that, unless otherwise noted, the contents of the FDA website (www.fda.gov) are not copyrighted and are in the public domain. This page is on the accessdata.fda.gov host of FDA; the policy page names www.fda.gov only, so the terms for this host are unverified and the source is cite_only: facts are stated in the atlas's own words, with no quoted span. The raw page is committed at research/snapshots/ch-fda-daf-nda215341.html.
    3. Supports FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record for application NDA215341 returned on 2026-10-14, from a dataset last updated 2026-10-13. It lists the applicant, products and submissions but gives the original approval date only as a compact number (YYYYMMDD), so the Drugs@FDA page is also kept as a snapshot. · NDA: NDA215341

      Locator
      results[0].submissions[3].submission_type; results[0].submissions[3].submission_status; results[0].submissions[3].submission_class_code_description
      How it applies
      Original submission, its status and classification.
      Retrieved
      Source effective date
      2026-10-13
      Source state
      Current
      Snapshot hash
      3ad75e163b866653015aee0b31d67725c3aaf788abe55d149f53d65ab1f3385e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-14 as ch-openfda-terms.html, sha256 b11f712bfb11, hash only). The raw record is committed at research/snapshots/ch-openfda-nda215341.json.
    4. Background FDA New Drug Application NDA215341: Kerendia (openFDA drugsfda record)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drugsfda record for application NDA215341 returned on 2026-10-14, from a dataset last updated 2026-10-13. It lists the applicant, products and submissions but gives the original approval date only as a compact number (YYYYMMDD), so the Drugs@FDA page is also kept as a snapshot. · NDA: NDA215341

      Locator
      results[0].products[0].active_ingredients[0].name
      How it applies
      Active ingredient on the application record.
      Retrieved
      Source effective date
      2026-10-13
      Source state
      Current
      Snapshot hash
      3ad75e163b866653015aee0b31d67725c3aaf788abe55d149f53d65ab1f3385e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-14 as ch-openfda-terms.html, sha256 b11f712bfb11, hash only). The raw record is committed at research/snapshots/ch-openfda-nda215341.json.

Authorization

Regulatory decision: Finerenone (Kerendia)

Applies to Recipient not specified
  • Not stated in the FDA application records read. The records give the applicant, the products and the submission history; the label record gives age limits for each indication.
  • Not stated in the FDA records
  • United States (decision by the US Food and Drug Administration)
  • Not stated in the FDA records
  • Gestational age Not reported
  • Postnatal age Not reported
Follow-up Not applicable (regulatory decision)
Decision
Approval,
Pathway
NDA
Submission
NDA215341
Jurisdictions
United States; note: United States
Product version
Kerendia (finerenone) tablets, application NDA215341, original submission ORIG-1
Indication
Not stated in the sources read. openFDA returned no label record for Kerendia.
Basis
The US Food and Drug Administration approved Kerendia (finerenone tablets) on 9 July 2021 under new drug application NDA215341. The Drugs@FDA page lists the original submission as ORIG-1, an approval, classified Type 1 - New Molecular Entity. The openFDA record lists the applicant as BAYER HLTHCARE.

Limitations. An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The date comes from the Drugs@FDA page, which writes it as a month-first slash date. The openFDA record gives the date only as a compact number, so the page is quoted. No label record for Kerendia was returned by openFDA, so this atlas states no indication. openFDA says not to rely on it for decisions about medical care.

A regulatory decision is separate from a guideline recommendation and from payment coverage.

Record details

Record id
cardio:kerendia
Content hash
2476aba340bcccd6df3c7e4d8f8b8870dad5ec3b995cecf4ac71f11becc5afb4